ストックスクリーナーアプリを入手
17.14
4.14%
-0.74
プレマーケット:
18.40
1.26
+7.35%
前日終値:
$17.88
開ける：
$17.41
24時間の取引高:
547.50K
Relative Volume:
1.79
時価総額：
$598.06M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.33%
1か月 パフォーマンス:
+1.42%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$16.78
$18.04
1週間の範囲:
$15.73
$18.89
52週間の値動き範囲:
$14.72
$25.58
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
名前
First Tracks Biotherapeutics Inc
セクター
電話
212-373-3000
住所
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
17.14 | 623.88M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | Leerink Partners | Outperform |
| 2026-04-24 | 開始されました | Wedbush | Outperform |
| 2026-04-23 | 開始されました | JP Morgan | Overweight |
| 2026-04-22 | 開始されました | Barclays | Overweight |
| 2026-04-21 | 開始されました | UBS | Buy |
First Tracks Biotherapeutics Inc (TRAX) 最新ニュース
[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (TRAX) director receives stock options and RSU grant - Stock Titan
First Tracks Biotherapeutics (TRAX) awards options and RSUs to director - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) gets equity awards - Stock Titan
First Tracks Biotherapeutics (TRAX) director awarded options and RSUs - Stock Titan
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com UK
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com Canada
TRAX Initiated Coverage by First Tracks -- Rating Set to Overwei - GuruFocus
Wells Fargo Initiates First Tracks Biotherapeutics at Overweight - Moomoo
AnaptysBio earnings up next: First report as royalty company - Investing.com
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
AnaptysBio Details Tax Treatment of Spin-Off Dividend - TipRanks
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan
First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis $TRAX - MarketBeat
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm
Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
Autoimmune drug biotech First Tracks to meet investors at Jefferies, Leerink - Stock Titan
TRAXV SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets - Yahoo Finance
Form 424B3 First Tracks Biotherapeu - StreetInsider
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan
First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan
First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan
Director at First Tracks Bio (NASDAQ: TRAX) receives new equity awards - Stock Titan
Director Magda Marquet granted options and RSUs at First Tracks (TRAX) - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) granted options and RSUs - Stock Titan
Director John A. Orwin receives new equity awards at First Tracks Biotherapeutics (TRAX) - Stock Titan
First Tracks (TRAX) awards director 42,000 options and 15,000 RSUs - Stock Titan
Executive equity awards at First Tracks Biotherapeutics (TRAX) detailed - Stock Titan
First Tracks (TRAX) CEO receives new stock options and RSU awards - Stock Titan
First Tracks Biotherapeutics (TRAX) CFO receives new option and RSU awards - Stock Titan
First Tracks Biotherapeutics, Inc. (TRAX) Cash From Financing (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Dividend (TTM) - Zacks Investment Research
This First Tracks Biotherapeutics analyst begins coverage on a bullish note; here are top 4 initiations for Monday - MSN
[EFFECT] First Tracks Biotherapeutics, Inc. SEC Filing - Stock Titan
Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus
TRAX Should I Buy - Intellectia AI
AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
First Tracks Biotherapeutics, Inc. (TRAX) - Zacks Investment Research
First Tracks Biotherapeutics Inc (TRAX) 財務データ
First Tracks Biotherapeutics Inc (TRAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):